FDAsafety guidance66% confidence
FDA AP — MYCOPHENOLATE MOFETIL (ORIG)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Strides Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA218566. Sponsor: CONCORD BIOTECH LTD. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: MYCOPHENOLATE MOFETIL.
Supporting Context
- Therapeutic area
- Immunology · Immunosuppressant
- Sub-indication
- General
Related signal: FDA Approval Process Update for Mycophenolate Mofetil by Strides Pharma